Ranibizumab port implant for wet macular degeneration in Chinese adults
Treatments studied
Part of Eyes & vision clinical trials.
This Phase 3 study tests whether a small eye implant that delivers medicine on a schedule (the port delivery system) with ranibizumab works better and safely in people with wet age-related macular degeneration. It’s designed for patients who have already been treated recently with anti-VEGF injections and need continued control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were first diagnosed with wet age-related macular degeneration within the last 9 months
- In the past 6 months, you received at least three anti-VEGF injections into the eye (standard-of-care)
- Your prior anti-VEGF injections showed a response (not total non-response)
- You have old vision records before your first anti-VEGF treatment
- Your vision is at least about 20/200 (34 ETDRS letters or better)
- Your eye doctor can get clear eye scans/photos for the study to grade your retina
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks how well corneal endothelial cells (cells that help keep the cornea clear) do in people with neovascular age-related macular degeneration (nAMD) who are treated with a port-delivery implant that releases ranibizumab. It also helps doctors understand whether this method changes corneal health and stays safe while controlling the eye disease.
This trial studies whether continuing treatment with a refillable eye implant (Port Delivery System) and ranibizumab injection helps control a specific type of wet macular degeneration. It’s mainly for people who already finished an earlier related study and are able to keep up with frequent eye checks and procedures.
This trial tests a refillable eye implant (PDS) that slowly releases medication to treat wet age-related macular degeneration (nAMD). It aims to see if replacing the implant every 36 weeks works as well as regular eye injections.
This trial tests a new treatment called IVB103 for people with wet age-related macular degeneration (AMD). It aims to see if the injection is safe and effective for those who have already had anti-VEGF therapy. You may qualify if you have active disease and have had at least two prior anti-VEGF treatments.
This study tests a new medicine called IBI302 for wet age-related macular degeneration (AMD). It aims to slow vision loss by targeting both blood vessel growth and inflammation. You might qualify if you have active wet AMD and have not had certain injections recently.
This trial tests a one-time gene therapy injection for wet AMD that may reduce the need for regular eye injections. It is for people who have already responded to anti-VEGF injections but want a longer-lasting treatment.
Hear when a new Neovascular Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.